Moderna (MRNA) Reports Interim Data From Phase 1 Study of mRNA-2752 Triplet Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Moderna (MRNA) Reports Interim Data From Phase 1 Study of mRNA-2752 Triplet Program
November 11, 2021 1:02 PM EST
Moderna (NASDAQ: MRNA) has recognized the substantial role that the NIAID has played in helping to develop Modernas COVID-19 vaccine by including NIAID scientists as co-inventors on published patent applications where they have made inventive contributions.
Under U.S. patent law, there are strict rules for determining who should be listed as inventors on a patent. Just because someone is an inventor on one patent application relating to our COVID-19... More
November 11, 2021 9:01 AM EST
Yesterday, Germany recommended only the Covid-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NYSE: BNTX) for under the 30s as it causes fewer heart inflammations in younger people than the Moderna (NASDAQ: MRNA).
The committee also recommended pregnant women receive only the BioNTech/Pfizer vaccine.
In the meantime, two... More
